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Abstract
Background:  The purpose of the present study was to evaluate the safety and the cost-
effectiveness of using preoperative IABP as support compared with postoperative IABP treatment
in coronary patients with severe left ventricular dysfunction (SLVD) who is undergoing off-pump
coronary artery bypass surgery (OPCAB), including early outcomes, hospital mortality and
morbidity, and mid-term follow-up outcomes.
Methods: Between March 2000 and December 2008, we prospectively and randomly studied the
insertion of preoperative IABP in 115 (7.4%) and postoperative IABP in 106 (6.8%) of the 1560
consecutive patients. Group A is preoperative IABP therapy. Group B is postoperative IABP
therapy.
Results: There was no significant difference in the number of grafts used between the two groups.
Completeness of revascularization did not differ between the two groups. The statistically
significant difference was hospital mortality (2.6% in group A vs. 3.8% in group B) (p < 0.05). And
there was significant reduction in postoperative low cardiac output, malignant arrhythmia, acute
renal failure and length of stay in ICU in group A, compared with group B (p < 0.05). In the two
groups, six-, 12-, 24- and 48-month survival rates were similar. In the study the degree of
improvement in angina and quality of life did not differ significantly between the two groups.
Conclusion: The use of preoperative IABP in SLVD patients undergoing OPCAB is of safety and
effectiveness. The combined use of preoperative IABP and OPCAB allows complete
revascularization in SLVD patients with an important reduction in operative mortality and excellent
mid-term results.
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Background
Despite improvements in medical therapies and surgical
techniques, the management of coronary patients with
severe left ventricular dysfunction (SLVD) (ejection frac-
tion [EF] = 0.35) is still challenging[1,2]. For this popula-
tion, CABG is associated with higher postoperative
morbidity and mortality compared with patients with
normal left ventricular function[3]. Off pump coronary
artery bypass surgery (OPCAB) has theoretical and practi-
cal advantages over conventional coronary artery bypass
grafting (CCABG)[4,5].
Also in high risk coronary patients, OPCAB is an attractive
alternative, but due to hemodynamic instability this
cohort of patients has usually been operated using some
circulatory support. The elective use of intra-aortic bal-
loon pump (IABP) in these patients may prevent this and
thus avoid the institution of CPB with its attendant risks
which include inflammation and global ischemia[6,7]
The use of pre- and postoperative IABP has been sug-
gested, but not yet fully explored[8,9]. The purpose of the
present study is to evaluate, in a prospective and rand-
omized manner, the safety and the effectiveness of using
preoperative IABP as support compared with postopera-
tive IABP treatment.
Patients and methods
Patients and inclusion criteria
The study was approved by the Institutional Review Board
in March 3, 2000, and informed consent was obtained
from all patients. Since March 2000, OPCAB has been the
technique of choice at our center for all isolated coronary
procedures, and it was used in 1560 consecutive patients.
Between March 2000 and December 2008, we prospec-
tively studied the insertion of preoperative Datascope sys-
tem IABP in 115 (7.4%) consecutive patients with poor
preoperative left ventricular ejection fraction (LVEF) =
35%. During the same period, the IABP was inserted dur-
ing or after the operation in 106 (6.8%) of the 1560
patients. The LVEF of all patients was calculated from
echocardiography assessment performed by an independ-
ent cardiologist.
Inclusion criteria
Adult patients with coronary artery disease (CAD) admit-
ted for elective or urgent myocardial revascularization by
OPCAB and classified as patients with severe left ventricu-
lar dysfunction according to definition given above and
judged suitable for OPCAB surgery by the responsible sur-
geon were included in study. Patients with moderate and
severe mitral regurgitation MR were excluded because of
our practice to perform mitral valve repair/replacement in
these patients at the initial procedure.
The patients fulfilling the above criteria were randomized
into either of two groups by lottery (prepared closed enve-
lopes containing the group assignment): Group A–preop-
erative IABP therapy, started 24 hour(h) prior to
induction of anesthesia, followed by continuous IABP
during the entire procedure as well as postoperatively.
Group B–postoperative IABP therapy, inserted during or
after the operation. Postoperative IABP treatment was ini-
tiated if fulfilling definitions stated: when CI cannot be
maintained at a level greater than 2.0 L/min/m2, despite
pharmacological support with epinephrine equal or more
than 0.5 μg/kg/min, dobutamine equal or more than 10
μg/kg/min and amrinonum equal or more than 0.5 mg/kg
bolus dose, an IABP treatment was indicated.
All preoperative clinical, operative data and follow-up
data were entered into a computer data base. Definitions
were laid prior to the start of the study and had not been
changed during the study period.
All the patients had multi-vessel coronary artery disease
with severe left ventricular dysfunction and other patients'
characteristics for each group are presented in Table 1. No
significant differences were found between two groups in
baseline variables such as age or comorbidities. The over-
all predicted risk according to the EuroScore was similar
between the two groups.
Intra-aortic balloon pump (IABP)
The IABP catheter used was 8 F 34 ml balloon Percor
STAT-DL Catheter (Datascope Corp, Fairfield, NJ) con-
nected to a Datascope portable computerized console
(Datascope), placed using percutaneous insertion tech-
nique via femoral artery. In group A, preoperative inser-
tion was normally performed in the anesthesia
preparation room in the operating room (OR) prior to
induction of anesthesia. Group B patients received their
IABP in the operating room if fulfilling definitions stated
above. There was no failure of percutaneous placement of
the IABP, while using the guide-wire. Unless heparin was
contraindicated, patients were therapeutically anticoagu-
lated with heparin after IABP placement. Patients return-
ing from the operating room with an IABP in place were
given Dextran until the mediastinal drainage removed
(usually within 24 h) for anticoagulation.
IABP therapy for group A was continued postoperatively
only when indicated based on restoration of hemody-
namic stability maintaining a CI greater than 2 L/min/m2,
with only minimal pharmacological inotropic support.
The same definition was used for termination of postop-
erative IABP for Group B.Journal of Cardiothoracic Surgery 2009, 4:39 http://www.cardiothoracicsurgery.org/content/4/1/39
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Surgical procedure
Standard intraoperative monitoring techniques were
used. A CPB circuit was on stand-by for all cases. All pro-
cedures were performed through a median sternotomy.
After the conduits (internal thoracic arteries, the radial
artery, and saphenous vein) were harvested, heparin was
administered to maintain an activated clotting time
greater than 250 seconds. Three deep left pericardial
sutures were used for cardiac exposure, and a suction
device (Octopus Evolution, Medtronic, Minneapolis,
MN) was used for stabilization of the coronary arteries. A
shunt (Chase Medical, Richardson, TX) was inserted in the
coronary artery during all anastomoses to avoid ischemic
damage and perioperative rhythm disturbances. A
blower/mister was systematically used to obtain a blood-
less operative field and perfect visualization of the coro-
nary artery. The left anterior descending artery was
revascularized first in all patients. In cases of vein grafting,
the proximal anastomosis of the vein on the aorta was
performed before the distal anastomosis under side
clamping. The IABP was placed on stand-by during the
proximal anastomosis. A cell-saving device was used in all
patients.
Preoperative, operative, and postoperative variables
between the groups were investigated, including hospital
mortality and morbidity rates, such as neurologic events,
perioperative infarction, renal insufficiency, rhythm dis-
turbances, respiratory failure, hospital length of stay, in-
hospital death and reoperations for excessive postopera-
tive bleeding or ischemia.
Mid-term follow up
Mid-term follow-up was achieved by direct telephone
contact with the patient, family, primary care physician,
or cardiologist. If necessary, additional information was
obtained from patient's hospital and office records. The
endpoints were return to work rates, disease specific qual-
ity of life (QOL) using Seattle Angina Questionnaire
(SAQ). The SAQ is a 19-item disease-specific self-adminis-
tered questionnaire assesses physical limitation, angina
frequency, treatment satisfaction and disease perception/
QOL[10]. Higher scores on SAQ subscales indicate better
levels of functioning. Patients were classified as employed
at baseline if they were working full- or part-time or were
on sick leave, with expectation of returning to work for
such patients was defined as working full- or part-time at
follow-up.
Statistics
Results are expressed as the mean value ± standard devia-
tion. Microsoft Excel was used for all statistical data
Table 1: Preoperative Characteristics
Variables Group A (n = 115)
N (%)
Group B (n = 106)
N (%)
P value
Female sex 42(36.5) 32 (30.2) 0.42
Age > 65 years 78 (67.8) 80 (75.5) 0.11
Symptom status(stable) 66 (57.4) 70 (66.0) 0.65
Diabetes 35 (30.4) 36 (34.0) 0.77
Hypertension 70 (60.9) 79 (74.5) 0.12
Hypercholesterolemia 85 (73.9) 76 (71.7) 0.88
Smoking 86 (74.8) 72(67.9) 0.61
Chronic Renal dysfunction 4 (3.5) 3 (2.8) 0.08
Chronic Gastritis 9 (7.8) 10 (9.4) 0.11
COPD 16 (13.9) 18 (17.0) 0.47
Peripheral vascular disease 7(6.1) 5 (4.7) 0.21
MI 73 (63.5) 79 (74.5) 0.06
Angina (CCS III/IV) 95 (82.6) 84 (79.2) 0.21
Dyspnea (NYHA III/IV) 55(47.8) 42 (39.6) 0.18
Redo CABG 2 (1.7) 1(0.9) 0.07
Prior CVA 5 (4.3) 3 (2.8) 0.11
BMI > 30 kg/m2 45 (39.1) 35 (33.0) 0.45
Aspirin<10 days 96 (83.5) 78(73.6) 0.17
Previous failed PTCA 8 (7.0) 8 (7.5) 0.64
Parsonnet score >10 73 (63.5) 73 (68.9) 0.37
Left main disease 20 (17.2) 21 (19.8) 0.58
Mean Diseased vessels 3.20 ± 0.36 3.42 ± 0.52 0.85
Mean EuroSCORE 12.58 ± 3.05 13.37 ± 3.13 0.26
Mean LVEF(%) 29.62 ± 5.32 30.04 ± 4.27 0.36
CCS = Canadian Cardiovascular Society score; COPD = chronic obstructive pulmonary disease; MI = myocardial infarction; CVA = 
cerebrovascular accident; GI = gastrointestinal; BMI = body mass index; PTCA = percutaneous transluminal coronary angioplasty;Journal of Cardiothoracic Surgery 2009, 4:39 http://www.cardiothoracicsurgery.org/content/4/1/39
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processing. Data were examined univariately by the
ANOVA test for continuous variables, and the χ2 analysis
was used for discrete data. After completion of the pro-
pensity model, a propensity score for mortality was calcu-
lated from the logistic equation for each patient. Then, on
this basis, patients were sorted by propensity and com-
pared within five quintiles [11]. Survival curves were
drawn on an actuarial basis using the Kaplan-Meier tech-
nique. Statistical significance was considered at a value of
p < 0.05. Data were analyzed using SPSS 13.0 (SPSS).
Results
Perioperative characteristics
There was no significant difference in the number of grafts
used between the two groups (Table 2). Group A patients
received 3.3 ± 0.6 grafts per patient, while group B patients
had 3.1 ± 0.5 (p = 0.36). There was no significant differ-
ence in the use of left internal mammary artery (LIMA),
right internal mammary artery and radial arterial grafts in
the two groups. The distribution of distal anastomosis was
similar between the two groups: 3.8 ± 0.5 in group A, and
3.6 ± 0.3 in group B (p = 0.24). Completeness of revascu-
larization did not differ between the two groups (group A
87.3% vs. group B 86.9%; p = 0.18). Coronary thromben-
darterectomy was required in 16(7.2%) cases, without
group differences.
Hospital Mortality
The only statistically significant difference was hospital
mortality (2.6% in group A vs. 3.8% in group B), which
showed significantly lower in group A (p = 0.031). In the
group A, the cause of death was right ventricular failure in
one patient with preoperative massive right ventricular
infarction, and multiple organ failure in two patient. But
in the group B, the cause of death was cardiac arrest in one
patient, and multiple organ failure in three patients.
Hospital Morbidity
There was no significant difference in neurologic events,
postoperative infarction, wound infection, respiratory
failure, new-onset atrial fibrillation and reoperations for
excessive bleeding between two groups (Table 3). How-
ever, there was significant reduction in postoperative low
cardiac output, malignant arrhythmia, acute renal failure
and length of stay in ICU in group A, compared with
group B. Only 12 patients(10.4%) in group A had postop-
erative low cardiac output in contrast 20 patient(18.9%)
in group B (p < 0.05). The ventricular arrhythmia occurred
in seven patient (6.1%) in group A and 13
patients(12.3%) in group B (p < 0.05). The acute renal
failure occurred in eight patients(6.9%) in group A and 12
patients(11.3%) in group B (p < 0.05). The prolonged
stay(≥3 days) in the ICU was 33.9% in group A and 54.7%
in group B (p < 0.05). The mean postoperative IABP time
was 2.2 ± 0.7 days in group A and 3.6 ± 1.3 days in group
B (p < 0.05).
IABP-Related Morbidity
Vascular complications occurred in 2 patients of group A
and in 3 patients of group B. There were two retroperito-
neal heamatomas and one distal limb ischemia (which
resolved with balloon removal). There was no IABP-
related mortality in group A or group B. No infections
occurred in either group. There was no complication
related to the use of heparin perioperatively in these
patients.
Mid-Term Follow-Up
Follow-up was achieved for survivors (mean follow-up
time: 48.4 ± 11.6 months). Two patients were lost to fol-
low-up in the group A, and three patients were lost in the
group B. Three patients died during follow-up: one
patient in group A from pulmonary neoplasm after 15
months, and one patient in group B from terminal renal
insufficiency after 13 months, another one patient in
group B from cerebrovascular accident after 3 years. No
Table 2: Operative Data
Variables Group A (n = 115)
N (%)
Group B (n = 106)
N (%)
p Value
Number of grafts Mean = 3.3 ± 0.6 Mean = 3.1 ± 0.5 0.36
Grafts, n(%)
2 SVG 18 (15.6) 19(17.9) 0.14
3 SVG 71 (61.7) 67(63.2) 0.26
4 SVG 26 (22.6) 20 (18.9) 0.13
LIMA 95 (82.6) 85(80.2) 0.64
RIMA 2 (1.7) 3 (2.8) 0.08
Radial 25 (21.7) 20(18.8) 0.19
Distal anastomosis(n) Mean = 3.8 ± 0.5 Mean = 3.6 ± 0.3 0.24
Complete revascularization 100 (87.0) 86 (81.1) 0.18
SVG = saphenous vein graft; LIMA = left internal mammary artery; RIMA = right internal mammary artery;Journal of Cardiothoracic Surgery 2009, 4:39 http://www.cardiothoracicsurgery.org/content/4/1/39
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major cardiac event due to incomplete revascularization
was reported during follow-up. There was no hemorrhag-
ing, thromboembolic complications, or stenosis during
follow-up. The Kaplan Meier survival curve, including
perioperative deaths, was presented in Fig. 1. In the two
groups, six-, 12-, 24- and 48-month survival rates were
similar.
All 81 survivors completed the SAQ questionnaire
(response rate 100%). At follow-up, physical limitation,
angina stability, angina frequency, treatment satisfaction
and quality of life were comparable between the two treat-
ment groups. In comparison with an age- and sex-
matched standard population, Group A and Group B
patients were impaired (score<85) in physical limitation
and in quality of life (Table 4).
Discussion
With the enormous growth of interventional cardiology in
recent years, patients coming to surgery for coronary
artery bypass grafting are often at the end-stage of their
disease, with severely impaired LV function. Management
of patients with SLVD caused by coronary artery disease
remains a challenge. The increased popularity and success
of OPCAB grafting during the past decade seems to be a
good surgical option. Good surgical results were obtained
from different study [12,13].
Earlier reports have shown that use of preoperative IABP
therapy can reduce myocardial ischemia and therefore
improve outcome in high-risk patients undergoing CABG
with the use of CPB[14]. Recent reports have indicated
that pre- and perioperative IABP therapy facilitates manip-
ulation of the heart with maintained hemodynamic sta-
bility and with reduced myocardial oxygen demand in
high-risk patients undergoing OPCAB surgery [15]. The
purpose of this study is to evaluate whether the use of pre-
operative intra-aortic balloon pump treatment can
improve the outcome after surgical myocardial revascular-
ization, and to evaluate whether this additional treatment
is safety and effectiveness.
Indications for preoperative insertion of IABP has usually
been reserved for patients with angina refractory to maxi-
mal medical therapy or for those with very low cardiac
output preoperatively[5]. Our selection criteria was specif-
ically designed to aggressively use the IABP preoperatively
in an effort to avoid the complications and mortality asso-
ciated with intraoperative or postoperatively inser-
tion(delayed insertion). We designed our study to
prospectively compare the results in two groups of
patients using a prospective and randomized manner.
The number of anastomoses per patient in the study was
similar to that in our current practice, as complete revas-
cularization remains the principal advantage of cardiac
operations and is essential in these patients, which corre-
sponds with results of earlier reports[5,16]. Our current
practice is to perform systematic off-pump operations for
all isolated coronary procedures, representing a group of
1560 consecutive patients for eight years.
This study compares mortality between the two groups of
patients receiving IABP. It is probably not surprising that
hospital mortality is lower for group A cases than for
group B cases. The improved hospital mortality in the pre-
operative IABP group compared with postoperative IABP
group most likely reflects the avoidance of progressive car-
diac dysfunction before insertion. Moreover, in the study
the benefit of OPCAB with IABP extended beyond the
early risk phase (the first year) and was not associated
with an increased mortality in the mid-term interval. Due
to the high risk of preoperative severely impaired LV func-
tion, the mortality is rather high for the series of patients.
Table 3: Hospital morbidity
Variables Group A (n = 115)
N (%)
Group B (n = 106)
N (%)
p value
Low Cardiac output 12 (10.4) 20(18.9) < 0.05
Reoperation for bleeding 8 (6.9) 6 (5.7) 0.08
IABP complication 0 0 -
Postoperative MI 2 (1.7) 2 (1.9) 0.54
New-onset atrial fibrillation 50 (43.5) 53 (50.0) 0.19
Ventricular arrhythmia 7 (6.1) 13 (12.3) < 0.05
Pleural effusion 78 (67.8) 76(72.0) 0.21
Wound infection 3 (2.6) 2 (1.9) 0.18
Acute Renal failure 8 (6.9) 12(11.3) < 0.05
Prolonged ventilatory support ≥ 24 h 38 (33.0) 42 (39.6) 0.16
Stroke and cerebrovascular accident 2 (1.7) 3 (2.8) 0.07
Prolonged stay (≥3 days) in ICU 39(33.9) 38(54.7) < 0.05
Postoperative IABP time(Days) 2.2 ± 0.7 3.6 ± 1.3 < 0.05Journal of Cardiothoracic Surgery 2009, 4:39 http://www.cardiothoracicsurgery.org/content/4/1/39
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And most of the deaths occurred in the early stage of the
study, related to our early experience. Three patients died
during follow-up, due to the non cardiac events.
In the present prospective randomized study, we have
clearly demonstrated that pre- and postoperative IABP
therapy are equally effective and safe, because of signifi-
cant decreases of the risk for hemodynamic instability and
conversion to CPB in coronary patients with SLVD. There
were no statistically significant differences in most clinical
outcome parameters between group A and group B, thus
indicating that the IABP therapy is effective as well, as ear-
lier documents[17]. However, it is notable that the pro-
longed stay in ICU as well as IABP support time was
significantly shorter for group A than group B. In the
present series, there were less IABP-related complications
that could be explained by the usage of small sized bal-
loon catheters (8F), an experienced team, short duration
of therapy and close surveillance.
Patients who received a preoperative IABP (group A) have
a lower rate of postoperative low cardiac output and ven-
tricular arrhythmia than those receiving postoperative
IABP (group B). This difference probably highlighted the
The Kaplan Meier survival curve Figure 1
The Kaplan Meier survival curve.
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Table 4: Quality of life
Variables* Group A (n = 110) Group B (n = 100) p Value
Physical limitation 77 ± 11 79 ± 12 0.88
Angina stability 90 ± 13 92 ± 15 0.86
Angina frequency 85 ± 14 88 ± 16 0.52
Treatment satisfaction 69 ± 9 71 ± 10 0.35
Quality of life 74 ± 10 78 ± 13 0.24
Return to work 31/110(28.2%) 25/100(22.7%) 0.31
*Quality of life assessment by Seattle Angina Questionnaire disease – specific instrument: score range from 0(worst) to 100(best health status)Journal of Cardiothoracic Surgery 2009, 4:39 http://www.cardiothoracicsurgery.org/content/4/1/39
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benefits of preoperative IABP in term of improved myo-
cardial oxygen supply/demand ratio, redistribution of
blood flow toward areas of ischemic myocardium, hemo-
dynamic stability during induction and prebypass and
improved graft flow postbypass[18]. In the study, eight
patients (6.9%) in group A and 12 in group A (11.3%)
developed acute renal dysfunction. This demonstrates
that preoperative elective IABP counterpulsation in high-
risk OPCAB surgery leads to a significant reduction in the
incidence of acute renal dysfunction and the need for
hemofiltration, which supports the finding of Vohra, et al
[19]. It has been proposed that the use of preoperative
IABP may lead to minimization of low-flow episodes with
avoidance of subsequent end organ dysfunction, espe-
cially OPCAB patients with SLVD.
Once the postoperative phase is achieved, our mid-term
follow-up shows excellent clinical results, with no subse-
quent revascularizations due to incomplete procedures,
thus confirming the adequacy of the revascularization. On
follow-up, most of the patients were free from angina,
rehospitalization and recatheterization both the two
groups postoperatively. In our study the degree of
improvement in angina and quality of life did not differ
significantly between the two groups. The SAQ question-
naire is more sensitive and responsive to detect changes in
angina-related health status than other generic measures
and it provides more clinically relevant information with
respect to the disease of interest [10]. Though the survival
curve of the preoperative IABP therapy group patients
appears to indicate slightly better early survival than the
postoperative IABP therapy group cohort, no statistical
difference was demonstrated.
Conclusion
The present study is limited by the small size of its popu-
lation. Further studies with a larger population are needed
to single out a group of heart failure patients, which could
benefit most from using intra-aortic balloon pump as a
supportive or bridge therapy. In conclusion this study has
demonstrated a beneficial effect of preoperative IABP
treatment in coronary artery patients with SLVD undergo-
ing OPCAB.
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